Therapeutic Monoclonal Antibodies and Multiple Sclerosis: The Essentials

E-ISSN： 1875-6638|14|2|144-154

ISSN： 1573-4064

Source： Medicinal Chemistry, Vol.14, Iss.2, 2018-02, pp. : 144-154

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Background: Monoclonal antibodies (mAbs) are now established as targeted therapies formalignancies, transplant rejection, autoimmune and infectious diseases. Two monoclonal antibodiesare available for treatment and other antibodies are currently being tested in multiple sclerosis (MS)patients.

Objectives: The purpose of the present review paper is to outline the antibody engineering technologies,the immunologic and pharmacologic concepts of mbs and the current status of treatment in MS withemphasis on clinical efficacy and safety.

Method: We conducted a through review of the scientific literature published until 31 December 2014(print and electronic publications) concerning the production, applications and side effects of the use ofMabs. Sixty five articles were used in total (both original research and review papers).

Conclusion: With the introduction of mAbs the treatment of MS has entered a new era, both with respectto efficacy and target specificity. However, administration of mAbs carries the risk of immunereactions such as acute anaphylaxis, serum sickness, infection and other autoimmune diseases. In addition,unexpected consequences arise from our incomplete knowledge of the immune system. For example,natalizumab, a monoclonal antibody targeting #945;4-integrin on leukocytes increases the risk ofdeveloping progressive multifocal leukoencephalopathy, without causing notable immunosuppression.Further study on the use of mabs is required, both in vitro and in the clinical field, in order to increaseour knowledge upon these new revolutionary therapeutic agents.